PATHOLOGICAL CHARACTERISTICS AND OPTIMAL DRUG SELECTION FOR BREAST CANCER WITH LOW HER2 EXPRESSION IN FEMALE ATHLETES

Abstract

With the advancement of new antibody-drug conjugates (ADCs), addressing breast cancer with low HER2 expression has emerged as a pivotal area of interest, especially in the context of female athletes. The biological and pathological profiles of breast cancers exhibiting low HER2 expression significantly diverge from other breast cancer types, presenting a complex challenge for late-stage treatment. Recent evidence has underscored the effectiveness of various ADCs in managing HER2-low breast cancer, highlighting the necessity for personalized treatment plans. The efficacy of these treatments appears to be influenced by the hormone receptor status of the patients, suggesting a tailored approach to drug selection is imperative. This article aims to review the clinical research focusing on low HER2 expression breast cancer in female athletes, exploring the use of ADC therapies and the implications of hormone receptor status on the decision-making process for treatment strategies.